404 Initial biomarker and clinical data of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced MSS-colorectal cancer
Richard D. Kim(Moffitt Cancer Center), Aung Naing(The University of Texas MD Anderson Cancer Center), Sara Ferrando‐Martínez(National Institutes of Health), Hirva Mamdani(Wayne State University), Jean Fan(Johns Hopkins University), Marya Chaney(Merck & Co., Inc., Rahway, NJ, USA (United States)), Melissa L. Johnson(Tennessee Oncology), Byung Ha Lee(OncoImmune (United States)), Ngocdiep T. Le(GlaxoSmithKline (United States)), Minal Barve(Mary Crowley Cancer Research Center)
Cited by 6
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain
|Nature Biotechnology|2017|1.1k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835